Tvaster Genkalp

Tvaster Genkalp is focused on developing advanced epigenetic-based liquid biopsies aimed at early detection and management of Hepatocellular Carcinoma (HCC), enhancing patient monitoring and treatment efficacy. Tvaster Genkalp, founded in 2021 in Chennai, India, specializes in epigenetic liquid biopsy solutions. The company has conducted one deal to date, with its most recent funding round on April 1, 2025, led by Ideaspring Capital, raising USD 1. 25 mn.

The founder's details are not disclosed, and there are no mentions of any subsidiaries or parent companies. Tvaster Genkalp specializes in an innovative epigenetic-based liquid biopsy specifically designed for the early detection, monitoring, and management of Hepatocellular Carcinoma (HCC). Their flagship product, the Episcreen Liver, employs a novel methodology integrating epigenetics and liquid biopsy techniques to identify genetic and epigenetic alterations related to liver cancer. This minimally invasive blood test caters primarily to patients with Chronic Liver Disease, specifically those at high risk due to hepatitis infection, cirrhosis, or a family history of liver cancer.

The company operates in various markets, focusing on healthcare providers, hospitals, and clinical laboratories, particularly in regions with high incidences of liver disease, though specific geographical markets have not been disclosed. Tvaster Genkalp's revenue structure is based on a transactional model involving direct engagement with healthcare providers and clinical laboratories. The company generates revenue through partnerships and collaborations for its liquid biopsy testing services. Clients engage Tvaster for episodic testing based on patient needs, particularly targeting chronic liver disease patients requiring regular monitoring for HCC.

The revenue model may also include subscription-based services for ongoing testing and data management, ensuring healthcare providers access the latest diagnostic information and treatment guidance, though exact pricing figures are not disclosed. In April 2025, Tvaster Genkalp raised USD 1. 25 mn in pre-Series A funding led by Ideaspring Capital, with participation from existing investor Invigo Software. The company plans to use these funds to accelerate the nationwide deployment of their groundbreaking technology, improving the accuracy and less invasiveness of cancer detection.

Future growth strategies include the design and launch of new products aimed at enhancing their diagnostic capabilities, as well as expanding into new markets and geographic regions, although specific markets and regions targeted for expansion have not been disclosed.